ClinicalTrials.gg
TerminatedNCT04495088Updated Oct 2, 2026

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

A Phase 3 interventional study of mFOLFOX (neoadjuvant) and XELOX (neoadjuvant) in Rectal Cancer, sponsored by Ralf Hofheinz. Terminated at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Ralf Hofheinz · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
poor accrual
Updated Oct 2, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
215
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing xelox in Rectal Neoplasms — 6 open to participants now, 8 under way, 1 of them phase 3. xelox · Rectal Neoplasms.

Enrollment
3rd of 16
215 · median 82
Started
2020
with 1 other
Phase 3
2 of 16
1 open now
Registered
7th of 16
by date
Lead sponsor
1 of 16
Ralf Hofheinz

Among the 16 studies testing xelox in Rectal Neoplasms, this one is the 3rd largest by enrollment, is one of 2 that started in 2020, is one of 2 in phase 3, and was the 7th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

6 of the 16 studies testing xelox in Rectal Neoplasms are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

About xelox

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing xelox in Rectal Neoplasms, or all of them as a file.
02

Study summary

This is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure

Read the detailed description

Patients with locally advanced rectal cancer are generally treated with preoperative 5-FU- or capecitabine-based chemo-radiotherapy (CRT) and total mesorectal excision (TME) surgery in order to decrease the rate of local failure. In patients with low risk for local failure in the middle third of the rectum (cT3a/b, N-) as determined with quality controlled MRI, the German S3 guidelines and the ESMO clinical practice guidelines state that neoadjuvant radiotherapy may be omitted. However, distant failure rate is still substantial in the range of 20-25% in these patients highlighting the need for more effective systemic treatment.

The hereby proposed ACO/ARO/AIO-18.2 randomized trial incorporates three novel aspects: (1) patient selection relies on strict and quality controlled MRI features and therefore identifies a cohort without imminent need for radiotherapy, (2) the sequence of chemotherapy and surgery is changed in a way that chemotherapy is administered preoperatively to increase the rate of patients treated with chemotherapy, and (3) three months of neoadjuvant FOLFOX or XELOX (instead of up to 6 months adjuvant chemotherapy) are used as a sole perioperative treatment in order to administer effective doses of the presumably most effective perioperative treatment at an early time point during the course of disease.

Thus, patients with locally advanced rectal cancer but low risk for local failure (cT1/2N+ in all thirds of the rectum, cT3a/b N- in the middle third, and cT3-4 Nany in the upper third) will be included and randomized between three months of neoadjuvant FOLFOX/XELOX in Arm A and primary resection of the tumor followed by risk (i.e. stage) adapted chemotherapy in Arm B.

03

Conditions studied

  • Rectal Cancer

Browse trials for

Keywords

  • Rectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients with confirmed diagnosis of rectal adenocarcinoma localised 0 - 16 cm from the anocutaneous line as measured by rigid rectoscopy (i.e. lower, middle and upper third of the rectum), depending on MRI-defined inclusion criteria (see below).
  2. Staging requirements: High-resolution magnetic resonance imaging (MRI) of the pelvis is the mandatory local staging procedure.
  3. Transrectal endoscopic ultrasound (EUS) is used to help discriminate between T1/2 and early T3 tumors.
  4. MRI-defined inclusion criteria:

    i. Lower third (0-6 cm):

    • cT1/2 with clear cN+ based on defined MRI criteria or T3a-b (i.e. maximum infiltration into the perirectal fat of 5mm), provided CRM > 2mm and EMVI-** ii. Middle third (≥ 6-12 cm):
    • cT1/2 with clear cN+ provided CRM- and EMVI-**
    • cT3 irrespective of the depth of invasion into the perirectal fat, provided no evidence that tumor is adjacent to (defined as within 2 mm of) the mesorectal fascia on MRI (i.e. CRM > 2 mm), N0 or N1, EMVI-** iii. Upper third (≥ 12-16 cm):
    • cT1/2 with clear cN+, irrespective of CRM and EMVI
    • any cT3-4 irrespective of nodal status, CRM and EMVI.
  5. Spiral-CT of the abdomen and chest to exclude distant .
  6. Aged at least 18 years. No upper age limit.
  7. Performance Status ≤1.
  8. Adequate haematological, hepatic, renal and metabolic function parameters:
  9. Leukocytes ≥ 3.000/mm³, ≥ 2.000/mm³, ≥ 100.000/mm³, > 9 g/dl
  10. Serum creatinine ≤ 1.5 x
  11. ≤ 2.0 mg/dl, -SGPT, and AP ≤ 3 x upper limit of normal.
  12. (Bazett**) ≤ 440 ms
  13. of the patient.

"**" Formula for QTc interval calculation (Bazett): QTc= ((QT) ̅" (ms)" )/√(RR (sec))= ((QT) ̅" (ms)" )/√(60/(frequency (1/min)))

Exclusion criteria

Exclusion Criteria:

  1. Distant (to be excluded by CT scan of the thorax and abdomen).
  2. Prior antineoplastic therapy for rectal cancer.
  3. Prior radiotherapy of the pelvic region.
  4. Major surgery within the last 4 weeks prior to inclusion.
  5. Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment.
  6. Subject (male or female) is not willing to use highly effective*** methods of during treatment and for 6 months (male or female) after the end of treatment Male patients treated with Oxaliplatin should take legal advice concerning sperm conservation before start of therapy and should additionally use a condom during treatment period. Their female partner of should also use an appropriate contraceptive measure.
  7. On-treatment participation in a clinical study in the period 30 days prior to inclusion.
  8. Previous or current drug abuse.
  9. Other concomitant antineoplastic therapy.
  10. Serious concurrent diseases, including neurologic or psychiatric disorders (incl. dementia and uncontrolled seizures), active, uncontrolled infections, active, disseminated coagulation disorder.
  11. cardiovascular disease in (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 6 months before enrolment.
  12. Chronic diarrhea (> grade 1 according ).
  13. Prior or concurrent ≤ 3 years prior to enrolment in study (Exception: non-melanoma skin cancer or cervical carcinoma FIGO stage 0-1), if the patient is continuously disease-free.
  14. Known allergic reactions or on study medication or to any of the other .
  15. Evidence of peripheral sensory neuropathy > grade 1 according to CTCAE version 5.0 (see appendix).
  16. Severe kidney dysfunction ( \< 30 ml/min).
  17. Recent or concurrent treatment with brivudine.
  18. Pernicious or other megaloblastic anaemia caused by vitamin B12 deficiency.
  19. Known dihydropyrimidine dehydrogenase deficiency.
  20. Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule (these conditions should be discussed with the patient before registration in the trial).

"***"highly effective (i.e. failure rate of \<1% per year when used consistently and correctly) methods: intravaginal and transdermal combined (estrogen and progestogen containing) hormonal contraception; injectable and implantable progestogen-only hormonal contraception; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomized partner; sexual abstinence (complete abstinence is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments).

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
215 participants (actual)

Study arms

  • Experimental
    A (experimental arm)

    The experimental arm A starts with 6 cycles of mFOLFOX or 4 cycles of XELOX. Surgery is scheduled four or six weeks after day 1 of the last mFOLFOX or XELOX cycle, respectively. No postoperative chemotherapy is planned

    Drug: mFOLFOX (neoadjuvant) · Drug: XELOX (neoadjuvant)

  • Active comparator
    B (control arm)

    In the standard arm B, patients undergo surgical resection of the primary tumor followed by stage- (risk-)adapted adjuvant chemotherapy 4-8 weeks after surgery according to recommendations of the S3 guidelines in analogy to colon cancer. Details of the recommended protocols are provided in the protocol.

    Drug: mFOLFOX (adjuvant) · Drug: XELOX (adjuvant) · Drug: Capecitabine (adjuvant) · Drug: infusional 5-FU/FA "AIO" regimen (adjuvant) · Drug: infusional 5-FU/FA "de Gramont" (adjuvant)

Interventions

  • DrugmFOLFOX (neoadjuvant)

    neoadjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.

    Also known as: Folinic acid, Oxaliplatin, 5-FU

  • DrugXeloxStudies of XeloxXelox pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    neoadjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.

    Also known as: Capecitabine, Oxaliplatin

  • DrugmFOLFOX (adjuvant)

    adjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.

    Also known as: Folinic acid, Oxaliplatin, 5-FU

  • DrugXeloxStudies of XeloxXelox pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    adjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.

    Also known as: Capecitabine, Oxaliplatin

  • DrugCapecitabineStudies of CapecitabineCapecitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    adjuvant application Capecitabine: 1,250 mg/m2 bid, po, on days 1-14 Cycles are repeated on day 22. A total of 8 cycles are administered.

    Also known as: Capecitabine

  • Druginfusional 5-FU/FA "AIO" regimen (adjuvant)

    Drug page: AdjuvantStudies of AdjuvantAdjuvant pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    adjuvant application Folinic acid 2h i.v. 500 mg/m² 5-FU 2,600mg/m² (24h infusion) Days 1, 8, 15, 22, 29, 36; cycle is repeated day 57 (representing one cycle); a total of 3 cycles should be administered.

    Also known as: 5-FU, Folinic acid

  • Druginfusional 5-FU/FA "de Gramont" (adjuvant)

    Drug page: AdjuvantStudies of AdjuvantAdjuvant pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    adjuvant application Folinic acid 2h i.v. 200 mg/m² days 1 and 2 5-FU 400mg/m² bolus followed by 600mg/m² 22h infusion days 1 and 2 The cycle is repeated day 15; a total of 12 cycles should be administered.

    Also known as: 5-FU, Folinic acid

06

What researchers measure

Primary outcomes

  1. disease-free survival

    time from randomisation to one of the following events: no surgery or non-radical (R2) surgery of the primary tumour, locoregional recurrence after R0/1 resection of the primary tumour, second primary colorectal or other cancer, metastatic disease or progression, or death from any cause, whichever occurred first.

    Time frame: up to 3 years

Secondary outcomes

  1. Acute and late toxicity

    assessment of acute and late toxicity according to NCI CTCAE version 5.0

    Time frame: From date of informed consent until the End of Treatment or 30 days after the last dose of study treatment

  2. Compliance (completion rate) of chemotherapy

    Rate of completion of administered chemotherapy

    Time frame: From date of randomization until end of chemotherapy, approx. 12 (arm A) respectively up to 34 (arm B) weeks after randomization

  3. Surgical morbidity and complications

    Surgical morbidity and complications if surgery is performed and events occur

    Time frame: After surgery, approx. 2 (arm B) respectively 20 (arm A) weeks after randomization

  4. Pathological UICC-staging, including pCR (ypT0N0) rate

    Pathological staging according UICC criteria, including detailed information about pathologically assessed complete response rate (ypT0N0)

    Time frame: After surgery, approx. 2 (arm B) respectively 20 (arm A) weeks after randomization

  5. R0 resection rate, Negative circumferential resection rate (CRM > 1mm)

    defined as microscopically margin negative resection with no gross or microscopic tumor remains in the area of the primary tumor and/or samples regional lymph nodes based on evaluation by the local pathologist

    Time frame: After surgery, approx. 2 (arm B) respectively 20 (arm A) weeks after randomization

  6. Tumor regression grading according to Dworak in the experimental arm

    Grading of tumor regression according to Dworak in the experimental arm

    Time frame: After surgery, approx. 2 (arm B) respectively 20 (arm A) weeks after randomization

  7. Rate of sphincter-sparing surgery

    Rate of sphincter-sparing surgery if surgery is performed

    Time frame: After surgery, approx. 2 (arm B) respectively 20 (arm A) weeks after randomization

  8. Rate of W&W with or without local regrowth

    Number of performed watch\&wait approaches with or without local regrowth compared to planned and performed surgery

    Time frame: Up to 5 years after end of treatment

  9. Cumulative incidence of local and distant recurrences

    Total number of local and distant recurrences, if they occur

    Time frame: Up to 5 years after end of treatment

  10. Overall survival

    Overall survival is defined as the time interval between the date of randomization and the date of death of any cause. Patients who are still alive when last traced will be censored at the date of last follow-up

    Time frame: Up to at least 3 years and until 5 years

  11. Patient reported outcome: Quality of life according to questionnaire EORTC-QLQ-C30

    Quality of life scores according to validated questionnaires EORTC-QLQ-C30, based on treatment arm, and surgical procedures. 30 questions; score values from 1 (not at all) to 4 (very much) respectively from 1 (very poor) to 7 (excellent). Score outcome depends on score type.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever occured first, assessed up to approximately 68 months

  12. Patient reported outcome: Quality of life according to questionnaire EORTC-QLQ-CR29

    Quality of life scores according to validated questionnaires EORTC-QLQ-CR29, based on treatment arm, and surgical procedures. 29 questions; score values from 1 (not at all) to 4 (very much). Score outcome depends on score type.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever occured first, assessed up to approximately 68 months

  13. Patient reported outcome: Functional outcome according to Wexner score

    Functional score according to validated Wexner score, based on treatment arm, and surgical procedures. 5 questions; five score values from "never" to "1 per day or more often". The more often the worse the outcome.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever occured first, assessed up to approximately 68 months

07

Study locations

1 site
  • Unversity Hospital Mannheim
    Mannheim, 68167, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2020 to primary completion in Jul 2026, 70 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Aug 2030 → Jul 2026 and completion Aug 2030 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2020
First posted
Jul 31, 2020
StartActual
Sep 30, 2020
Primary completionActual
Jul 31, 2026was Aug 2030
CompletionActual
Jul 31, 2026was Aug 2030
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated poor accrual
changed Oct 2, 2026
Primary completion
Aug 2030→Jul 31, 2026 (actual)
Oct 2, 2026
Study completion
Aug 2030→Jul 31, 2026 (actual)
Oct 2, 2026
Enrollment
550 (estimated)→215 (actual)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Recruiting→Terminated
    Why stopped poor accrual
    Primary completion Aug 2030→Jul 31, 2026 (now actual)
    Study completion Aug 2030→Jul 31, 2026 (now actual)
    Enrollment 550 (estimated)→215 (actual)
    + 4 other changes: identifiers, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04495088
Lead sponsor
Ralf Hofheinz
Collaborators
Deutsche Krebshilfe e.V., Bonn (Germany), Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, German Rectal Cancer Study Group
Responsible party
Ralf Hofheinz (Prof. Dr., Universitätsmedizin Mannheim) — Sponsor-investigator
First posted
Jul 31, 2020
Start date
Sep 30, 2020
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026
Last update
Oct 2, 2026

Study contacts

Ralf-Dieter Hofheinz, Prof. Dr.
principal investigator · Universitätsmedizin Mannheim

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Xelox

Start the discussion